Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 8 de 8
Filtrar
1.
Clin Appl Thromb Hemost ; 20(3): 278-84, 2014 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-23478570

RESUMO

Platelets play an important role in various thrombotic diseases, including myocardial infarction. Because red wine consumption is inversely associated with death due to ischemic heart diseases, the effects of grape components on platelet function have been extensively investigated. Grape seed extracts (GSEs) reportedly inhibit platelet aggregation; however, the underlying mechanism has not been elucidated. We discovered that GSEs inhibit platelet aggregation induced by collagen and thrombin-receptor agonist peptide and increase basal levels of tyrosine phosphorylation, which was also observed in the presence of a protein tyrosine phosphatase (PTP) inhibitor. An in vitro phosphatase assay indicated that GSE dose dependently inhibited PTP-1B and Src homology 2 domain-containing phosphatase-1 activity, which positively regulates platelet aggregation. We propose that GSEs inhibit platelet aggregation by inhibiting tyrosine phosphatase activity. Moreover, we showed that GSE ingestion inhibited platelet aggregation in mice without enhancing tail bleeding, implying that GSE supplementation might be beneficial to prevention of thrombotic diseases.


Assuntos
Plaquetas/efeitos dos fármacos , Inibidores Enzimáticos/farmacologia , Extrato de Sementes de Uva/farmacologia , Ativação Plaquetária/efeitos dos fármacos , Agregação Plaquetária/efeitos dos fármacos , Proteínas Tirosina Fosfatases/antagonistas & inibidores , Animais , Plaquetas/citologia , Plaquetas/metabolismo , Masculino , Camundongos , Camundongos Endogâmicos C57BL , Proteínas Tirosina Fosfatases/metabolismo
2.
Undersea Hyperb Med ; 40(4): 351-62, 2013.
Artigo em Inglês | MEDLINE | ID: mdl-23957206

RESUMO

Over the past 50 years hyperbaric oxygen (HBO2) therapy has been used in a wide variety of medical conditions, and one of them is cancer. Many clinical studies have been conducted to evaluate potential therapeutic effects of HBO2 as a part of cancer treatment. This review briefly summaries the potential role of HBO2 therapy in the treatment of malignant tumors and radiation injury of the brain. HBO2 therapy is used for the enhancement of radiosensitivity in the treatment of some cancers, including malignant brain tumors. Radiotherapy within 15 minutes following HBO2 exposure, a relatively new treatment regimen, has been studied at several institutes and has demonstrated promising clinical results for malignant gliomas of the brain. HBO2 therapy also increases sensitivity to some antineoplastic agents; non-randomized clinical trials using carboplatin-based chemotherapy combined with HBO2 show a significant advantage in survival for recurrent malignant gliomas. The possibilities of combining HBO2 therapy with radiotherapy and/or chemotherapy to overcome newly diagnosed and recurrent malignant gliomas deserve extensive clinical trials. HBO2 therapy also shows promising potential for the treatment and/or prevention of radiation injury of the brain after stereotactic radiosurgery for brain lesions. The possibilities with HBO2 to enhance the therapeutic effect of irradiation per se, and to even increase the radiation dose if there are ways to combat the side effects, should boost new scientific interest into the whole field of oncology looking for new armamentaria to fight cancer.


Assuntos
Neoplasias Encefálicas/terapia , Encéfalo/efeitos da radiação , Glioma/terapia , Oxigenoterapia Hiperbárica , Lesões por Radiação/terapia , Antineoplásicos/uso terapêutico , Neoplasias Encefálicas/tratamento farmacológico , Neoplasias Encefálicas/radioterapia , Carcinoma de Células Escamosas/terapia , Hipóxia Celular , Terapia Combinada/métodos , Resistencia a Medicamentos Antineoplásicos/fisiologia , Humanos , Lesões por Radiação/prevenção & controle , Tolerância a Radiação/fisiologia
3.
Int J Radiat Oncol Biol Phys ; 82(2): 732-8, 2012 Feb 01.
Artigo em Inglês | MEDLINE | ID: mdl-21420247

RESUMO

PURPOSE: To analyze the long-term results of a Phase II trial of radiotherapy given immediately after hyperbaric oxygenation (HBO) with multiagent chemotherapy in adults with high-grade gliomas. METHODS AND MATERIALS: Patients with histologically confirmed high-grade gliomas were administered radiotherapy in daily 2 Gy fractions for 5 consecutive days per week up to a total dose of 60 Gy. Each fraction was administered immediately after HBO, with the time interval from completion of decompression to start of irradiation being less than 15 minutes. Chemotherapy consisting of procarbazine, nimustine, and vincristine and was administered during and after radiotherapy. RESULTS: A total of 57 patients (39 patients with glioblastoma and 18 patients with Grade 3 gliomas) were enrolled from 2000 to 2006, and the median follow-up of 12 surviving patients was 62.0 months (range, 43.2-119.1 months). All 57 patients were able to complete a total radiotherapy dose of 60 Gy immediately after HBO with one course of concurrent chemotherapy. The median overall survival times in all 57 patients, 39 patients with glioblastoma and 18 patients with Grade 3 gliomas, were 20.2 months, 17.2 months, and 113.4 months, respectively. On multivariate analysis, histologic grade alone was a significant prognostic factor for overall survival (p < 0.001). During treatments, no patients had neutropenic fever or intracranial hemorrhage, and no serious nonhematologic or late toxicities were seen in any of the 57 patients. CONCLUSIONS: Radiotherapy delivered immediately after HBO with multiagent chemotherapy was safe, with virtually no late toxicities, and seemed to be effective in patients with high-grade gliomas.


Assuntos
Astrocitoma/radioterapia , Neoplasias Encefálicas/radioterapia , Oxigenoterapia Hiperbárica , Neoplasias Supratentoriais/radioterapia , Adulto , Idoso , Idoso de 80 Anos ou mais , Protocolos de Quimioterapia Combinada Antineoplásica/efeitos adversos , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Astrocitoma/tratamento farmacológico , Astrocitoma/mortalidade , Astrocitoma/patologia , Astrocitoma/terapia , Neoplasias Encefálicas/tratamento farmacológico , Neoplasias Encefálicas/mortalidade , Neoplasias Encefálicas/patologia , Neoplasias Encefálicas/terapia , Terapia Combinada/métodos , Fracionamento da Dose de Radiação , Feminino , Seguimentos , Glioblastoma/tratamento farmacológico , Glioblastoma/mortalidade , Glioblastoma/patologia , Glioblastoma/radioterapia , Humanos , Oxigenoterapia Hiperbárica/efeitos adversos , Masculino , Pessoa de Meia-Idade , Análise Multivariada , Nimustina/administração & dosagem , Procarbazina/administração & dosagem , Tolerância a Radiação , Neoplasias Supratentoriais/tratamento farmacológico , Neoplasias Supratentoriais/mortalidade , Neoplasias Supratentoriais/patologia , Vincristina/administração & dosagem , Adulto Jovem
4.
Nucl Med Biol ; 36(8): 949-54, 2009 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-19875051

RESUMO

Enhancement of glucose utilization in the brain has been well known during acute seizure in various kinds of animal model of epilepsy. This enhancement of glucose utilization might be related to neural damage in these animal models. Recently, we found that methyl ethyl ketone (MEK) had both anticonvulsive and neuroprotective effects in lithium-pilocapine (Li-pilo) status epilepticus (SE) rat. In this article, we measured the uptake of [(14)C]2-deoxyglucose ([(14)C]DG) in the Li-pilo SE and Li-pilo SE with MEK rat brain in order to assess whether the glucose utilization was a useful biomarker for the detection of efficacy of anticonvulsive compounds. Significant increase of [(14)C]DG uptake (45 min after the injection) in the cerebral cortex, hippocampus, amygdala and thalamus during acute seizure induced by Li-pilo were observed. On the other hand, the initial uptake of [(14)C]DG (1 min after the injection) in the Li-pilo SE rats was not different from the control rats. Therefore, the enhancement of glucose metabolism during acute seizure was due to the facilitation of the rate of phosphorylation process of [(14)C]DG in the brain. Pretreatment with MEK (8 mmol/kg) completely abolished the enhancement of glucose utilization in the Li-pilo SE rats. The present results indicated that glucose utilization in the brain during acute seizure might be a useful biomarker for the evaluation of efficacy of anticonvulsive compounds.


Assuntos
Anticonvulsivantes/administração & dosagem , Encéfalo/metabolismo , Butanonas/administração & dosagem , Epilepsia/tratamento farmacológico , Epilepsia/metabolismo , Glucose/metabolismo , Cloreto de Lítio , Pilocarpina , Animais , Biomarcadores/metabolismo , Encéfalo/diagnóstico por imagem , Encéfalo/efeitos dos fármacos , Avaliação Pré-Clínica de Medicamentos/métodos , Epilepsia/diagnóstico por imagem , Masculino , Cintilografia , Ratos , Ratos Wistar
5.
Neurosci Lett ; 462(3): 300-2, 2009 Oct 25.
Artigo em Inglês | MEDLINE | ID: mdl-19607878

RESUMO

Significant increases in local cerebral blood flow during lithium-pilocarpine (Li-P) induced seizure have been reported. We recently found that both acetone and methyl ethyl ketone (MEK) showed anticonvulsive effects in status epilepticus induced by Li-P in rats. In this study, we examined whether MEK also suppressed the enhancement of local cerebral blood flow induced by Li-P with a simplified autoradiographic method using [(14)C]-para-iodo-N-isopropyl amphetamine ([(14)C]-IMP). Significant increases in local cerebral blood flow in the thalamus, hypothalamus, hippocampus and cerebellum were observed in Li-P induced status epilepticus rats. Pretreatment with MEK (8 mmol/kg) completely suppressed the enhancement of local cerebral blood flow to or below the control level in all regions.


Assuntos
Anticonvulsivantes/farmacologia , Butanonas/farmacologia , Circulação Cerebrovascular/efeitos dos fármacos , Cloreto de Lítio , Pilocarpina , Estado Epiléptico/tratamento farmacológico , Animais , Anticonvulsivantes/uso terapêutico , Autorradiografia , Butanonas/uso terapêutico , Radioisótopos de Carbono , Cerebelo/irrigação sanguínea , Hipocampo/irrigação sanguínea , Hipotálamo/irrigação sanguínea , Iofetamina/metabolismo , Masculino , Ratos , Ratos Wistar , Estado Epiléptico/induzido quimicamente , Estado Epiléptico/fisiopatologia , Tálamo/irrigação sanguínea
6.
Brain Res ; 1039(1-2): 199-202, 2005 Mar 28.
Artigo em Inglês | MEDLINE | ID: mdl-15781062

RESUMO

To obtain PET imaging of glucose metabolism in the brains of conscious rats, a method of rat head fixation was developed. PET measurement with microPET was performed for 60 min after 18F-FDG injection. Significant enhancement of glucose utilization in the right striatum was observed with infusion of Rp-adenosine-3,5-cyclic phosphorothioate triethylamine (Rp-cAMPS). FDG uptake increments were also seen in the ipsilateral frontal cortex and thalamus. As initial FDG uptake in the brain was not significantly altered by Rp-cAMPS, increased glucose metabolism might be due to an increase in the phosphorylation rate by hexokinase rather than the delivery process from plasma to the brain. In contrast to awake rats, the effect of Rp-cAMPS was abolished by anesthesia using chloral hydrate, indicating that neuronal activity has an important role in short term regulation of hexokinase activity through the cAMP/PKA system in the brain. These results strongly demonstrated the value of measuring glucose utilization in the brains of conscious rats.


Assuntos
Mapeamento Encefálico/métodos , Encéfalo/diagnóstico por imagem , AMP Cíclico/análogos & derivados , Fluordesoxiglucose F18/metabolismo , Tomografia por Emissão de Pósitrons/métodos , Inibidores de Proteínas Quinases/farmacologia , Tionucleotídeos/farmacologia , Anestésicos/farmacologia , Animais , Glicemia/metabolismo , Encéfalo/efeitos dos fármacos , Encéfalo/metabolismo , Corpo Estriado/efeitos dos fármacos , Corpo Estriado/metabolismo , AMP Cíclico/farmacologia , Lobo Frontal/efeitos dos fármacos , Lobo Frontal/metabolismo , Lateralidade Funcional/fisiologia , Masculino , Taxa de Depuração Metabólica , Modelos Animais , Compostos Radiofarmacêuticos/farmacologia , Ratos , Ratos Wistar , Tálamo/efeitos dos fármacos , Tálamo/metabolismo , Vigília/efeitos dos fármacos , Vigília/fisiologia
8.
J Biol Chem ; 277(24): 21561-6, 2002 Jun 14.
Artigo em Inglês | MEDLINE | ID: mdl-11943772

RESUMO

The glycoprotein VI (GPVI)-Fc receptor (FcR) gamma-chain complex, a key activatory receptor for collagen on platelet surface membranes, is constitutively associated with the Src family kinases Fyn and Lyn. Molecular cloning of GPVI has revealed the presence of a proline-rich domain in the sequence of GPVI cytoplasmic tail which has the consensus for interaction with the Src homology 3 (SH3) domains of Fyn and Lyn. A series of in vitro experiments demonstrated the ability of the SH3 domains of both Src kinases to bind the proline-rich domain of GPVI. Furthermore, depletion of the proline-rich domain in GPVI (Pro(-)-GPVI) prevented binding of Fyn and Lyn and markedly reduced phosphorylation of FcR gamma-chain in transiently transfected COS-7 cells, but did not affect the association of the gamma-chain with GPVI. Jurkat cells stably transfected with wild type GPVI show robust increases in tyrosine phosphorylation and intracellular Ca2+ in response to the snake venom convulxin that targets GPVI. Importantly, convulxin is not able to activate cells transfected with Pro(-)-GPVI, even though the association with the immunoreceptor tyrosine-based activation motif-containing chains is maintained. These findings demonstrate that the proline-rich domain of GPVI mediates the association with Fyn/Lyn via their SH3 domain and that this interaction initiates activation signals through GPVI.


Assuntos
Glicoproteínas da Membrana de Plaquetas/química , Prolina/química , Proteínas Proto-Oncogênicas/metabolismo , Quinases da Família src/metabolismo , Animais , Plaquetas/metabolismo , Células COS , Cálcio/metabolismo , Linhagem Celular , DNA Complementar/metabolismo , Escherichia coli/metabolismo , Citometria de Fluxo , Glutationa Transferase/metabolismo , Humanos , Immunoblotting , Ligantes , Mutagênese Sítio-Dirigida , Fosforilação , Testes de Precipitina , Ligação Proteica , Estrutura Terciária de Proteína , Proteínas Proto-Oncogênicas c-fyn , Proteínas Recombinantes de Fusão/metabolismo , Transdução de Sinais , Fatores de Tempo , Transfecção , Domínios de Homologia de src
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA